<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FA0C456-C4AE-4F71-98BD-478B27A5CFA5"><gtr:id>0FA0C456-C4AE-4F71-98BD-478B27A5CFA5</gtr:id><gtr:name>Metaltech Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D79E6E6-8FF2-44DC-8881-97666C523E2C"><gtr:id>5D79E6E6-8FF2-44DC-8881-97666C523E2C</gtr:id><gtr:name>Sanovo Technology Group</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FA0C456-C4AE-4F71-98BD-478B27A5CFA5"><gtr:id>0FA0C456-C4AE-4F71-98BD-478B27A5CFA5</gtr:id><gtr:name>Metaltech Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D79E6E6-8FF2-44DC-8881-97666C523E2C"><gtr:id>5D79E6E6-8FF2-44DC-8881-97666C523E2C</gtr:id><gtr:name>Sanovo Technology Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/464D389D-37E8-4F35-8E73-3DE6F1D2DA17"><gtr:id>464D389D-37E8-4F35-8E73-3DE6F1D2DA17</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Harvey</gtr:otherNames><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14123"><gtr:id>614DA025-DCA9-4DDC-892B-BB619C83F240</gtr:id><gtr:title>University of Birmingham MRC Proximity to Discovery: Open Innovation Through Local
Integration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14123</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>200000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Davor Pavlovic and AstraZeneca - Prevention of cardiac hypertrophy via inhibition of MAP kinase signaling pathway</gtr:description><gtr:id>AEDA9606-FD7B-4897-9792-FC6573C25AA7</gtr:id><gtr:impact>Data generated demonstrate that MAP kinase inhibition can be exploited as anti hypertrophic therapy. 
Data will be shared with AstraZeneca in the next two weeks and funding for further in cellulo and in vivo experiments will be requested from AstraZeneca. 
The in cellulo experiments require confirmation in a hypertrophy mouse model prior to clinical translation.</gtr:impact><gtr:outcomeId>58b82ed3175162.53232168-1</gtr:outcomeId><gtr:partnerContribution>AZ provided two MAP kinase inhibitor compounds</gtr:partnerContribution><gtr:piContribution>We proposed to test the efficacy of two MAP kinase inhibitors on prevention of hypertrophy in cardiac cells first, and then once the cellular experiments are completed, we would examine their effectiveness in our mouse hypertrophy/heart failure model. 
Now completed the in cellulo experiments. The two compounds that AstraZeneca have provided both reduced level of hypertrophy in isolated cardiomyocytes and iPS derived cardiomyocytes.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Metaltech Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Felicity de Cogan and Metaltech - Self cleaning surfaces</gtr:description><gtr:id>1AD66760-42E5-4FE6-A176-81F28C078011</gtr:id><gtr:impact>Multi - medical and engineering</gtr:impact><gtr:outcomeId>58b832c1271dd8.31348887-1</gtr:outcomeId><gtr:partnerContribution>Coating of prototype surfaces</gtr:partnerContribution><gtr:piContribution>This visit is to meet with Surg Capt Sarah Stapley in Falmouth to identify an appropriate surface which the industrial collaborator can nitride and UoB can coat to allow a project to be set up to test the efficacy of the technology. The project was carried out successfully. Prototype surfaces were delivered to Surg. Capt. Sarah Stapley. After 4 months of testing, samples were returned for testing. The meeting was successful and a collaboration was set up.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Research fellowship</gtr:description><gtr:id>32E2FD59-3022-4C21-A934-8ECF45031B96</gtr:id><gtr:impact>Conference presentation
Publications in preparation</gtr:impact><gtr:outcomeId>58c7a729cdefe9.78582530-1</gtr:outcomeId><gtr:partnerContribution>Funded research fellow</gtr:partnerContribution><gtr:piContribution>EU funded research fellowship for Nico Buettner to visit our laboratory for 2 years</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanovo Technology Group</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Development of low cost passive vaccination tools based on IgY</gtr:description><gtr:id>3956F2E7-BB40-4115-828D-B0ED3FD0CBB5</gtr:id><gtr:impact>Immunology, vaccinology, protein production,</gtr:impact><gtr:outcomeId>58c70c4d961f53.75227564-1</gtr:outcomeId><gtr:partnerContribution>Please see above</gtr:partnerContribution><gtr:piContribution>As a result of funding from CiC I have met with representatives of Sanovo. We have signed a MTA and are currently identifying how to perform proof-in-principle experiments on how to manufacture cheap, passive vaccines consumed by travellers as they go from high income, low infection risk, to low income, high infection risk environments. The company will generate the IgY based on our immunogens. This is still ata very early stage.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>296751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (Steve Watson)</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/16/53/32242</gtr:fundingRef><gtr:id>363748A2-F570-4C60-B88C-5973BCF82A36</gtr:id><gtr:outcomeId>58b84536c239e7.09992757</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Grand Challenge Shortlist (Graham Taylor)</gtr:description><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>6888BBAF-CF70-41F5-9C52-AEE81314117B</gtr:id><gtr:outcomeId>58b83ff5d552a7.11560337</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC/HEIF collaboration fund (Naomi Pollock)</gtr:description><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>95FEFBE0-A8DA-4013-9B15-D422FE4A0E75</gtr:id><gtr:outcomeId>58b8440a280cc1.43488799</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (Francis Mussai)</gtr:description><gtr:fundingOrg>Bio-Cancer Treatment International</gtr:fundingOrg><gtr:id>B42EACAC-533A-4044-A484-477642DAFB89</gtr:id><gtr:outcomeId>58b83ee4e98422.81321189</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprise Fellowship (Felicity de Cogan)</gtr:description><gtr:fundingOrg>Royal Academy of Engineering</gtr:fundingOrg><gtr:id>6EA59CA6-36AE-4674-8D61-94CEEA2127E3</gtr:id><gtr:outcomeId>58b8342f713d35.07211326</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprising Birmingham Fund (Felicity de Cogan)</gtr:description><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>28B1F5E6-F01E-4920-9965-3E8E0DDD336E</gtr:id><gtr:outcomeId>58b8337607e9f8.99306959</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Institutional Strategic Support Fund - Individual Research Award (Naomi Pollock)</gtr:description><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>5247336B-1B06-462E-9B83-B20F3313C9DA</gtr:id><gtr:outcomeId>58b8439727b721.47933342</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Provided is a nitrided metal surface functionalized with molecules, each molecule comprising at least one binding group and an antimicrobial moiety. The molecules are immobilized on the surface by only covalent interactions between the binding groups of the molecules and nitrogen atoms within the nitrided metal surface. Articles comprising the functionalized nitrided surface find use in inhibiting or reducing the growth of microorganisms on surfaces that are frequently touched. A method for preparing the functionalized nitrided surface comprises contacting a nitrided metal surface with molecules so as to form covalent bonds between the binding groups of the molecules and the nitrogen atoms in the surface, thereby immobilising the molecules on the metal surface.</gtr:description><gtr:grantRef>MC_PC_14123</gtr:grantRef><gtr:id>2FB80277-4403-44DD-BFEA-C7147FC6C3A5</gtr:id><gtr:impact>Discussions taking place with industrial collaborator around formation of spin out company. Enterprise Fellowship awarded.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58b83723b240a0.38350696</gtr:outcomeId><gtr:patentId>WO2017006139 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Antimicrobial surface</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14123</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>